# A Multiple Ascending Dose Study Evaluating the Safety and Tolerability of a Novel Formulation of QRL-101 in Healthy Participants

> **NCT07421778** · PHASE1 · RECRUITING · sponsor: **QurAlis Corporation** · enrollment: 48 (estimated)

## Conditions studied

- Healthy Participant Study

## Interventions

- **DRUG:** QRL-101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07421778
- **Lead sponsor:** QurAlis Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-02
- **Primary completion:** 2026-08-31
- **Final completion:** 2026-08-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07421778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07421778, "A Multiple Ascending Dose Study Evaluating the Safety and Tolerability of a Novel Formulation of QRL-101 in Healthy Participants". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07421778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*